share_log

Esperion Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition

SEC ·  Apr 3, 2023 20:13
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 334

Recommended